Phase I & II clinical trial expertise

Our substantial experience of developing and conducting adaptive protocols for Phase I and II trials enables us to maximise the return on our sponsors’ studies whilst guaranteeing the safety of our participants.

x

Benefits of using our Phase I & II clinical trials

Adding value by gathering more and highly relevant data. We only collect and analyse essential data to meet the trial objectives within a limited budget.

We limit assessments and participant exposure to what is relevant and essential. Tailoring our adaptive limits and control mechanisms for each protocol to manage potential risks.

Umbrella protocols to maximise efficiency. We integrate ethnic comparison elements, intensive cardiac assessments, and other biomarkers into a combined umbrella protocol - avoiding potential risks in further drug development.

We maximise return on our sponsors' trials

Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.

Get in touch today

Why choose Richmond Pharmacology for your Early Phase Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Systematic and logical protocols

We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.

Read more +

Competent and fast decisions

We guarantee rapid progression of your trial.

Read more +

Rapid approval

We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.

Read more +

Time efficient

Fast and efficient adaptive protocol development using a transparent and systematic approach.

Read more +

Our adaptive protocols enable immediate implementation of adaptive changes leading to early decision making and efficient use of essential data outputs.

Latest news

Samarjit Singh promoted to New Director of Clinical Operations

August 30, 2022
Richmond Pharmacology is delighted to announce the promotion of Samarjit Singh into the position of Director of Clinical Operations.
Read more

Transforming clinical trials to accelerate drug development – Keith Berelowitz

August 23, 2022
Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event